As the CEO, Hugues leads the company’s successful direction and advancement in all activities related to business ventures. He serves as a member on our Board of Directors and heads our Executive Committee.

Hugues brings more than fifteen years’ expertise as a CEO and serial entrepreneur in the Life Sciences and Biotechnology industries to the global team of experts at Univercells Group. Prior to founding Univercells Group, he acted as CEO at MaSTherCell (a leading CMO for cell therapy acquired by Catalent in 2020), Artelis (an innovator and leader in cell culture process optimization), and Kitozyme (a world-leading manufacturer of vegetable chitosan).

Hugues Bultot holds a master’s degree in law from UCL, Belgium, an executive master’s degree in business administration from Solvay Business School, Belgium, in tax management from ICHEC in Belgium, and certification in innovation from MIT’s Sloan School of Management in the United States.

José is the CTO and the architect of highly efficient production processes that break the barriers to biomanufacturing. A recognized technology leader in the biopharmaceutical industry, José brings a strong track record in innovative processes design and successful commercialization.

Previous accomplishments include the start-up of Artelis, where he designed and developed bioreactors that transformed industrial operations – the iCellis system being now considered as standard in the vaccines and gene therapy industry. The technology was industrialized at ATMI LifeSciences and Pall Lifesciences, where José held the position of Cell Culture Technologies Director. Prior to Artelis, José was Head of Viral Vaccine Industrialization at GSK Vaccines.

With a background in Chemical Engineering, Jose’s education includes a PhD in Applied Sciences from the Université Libre de Bruxelles, and an entrepreneurship degree from the Solvay Business School.

Mathias joined Univercells in 2015 as Chief Financial Officer to conduct Univercells’ financial strategy and fundraising activities. Then he acted as a Chief Commercial Officer between May 2017 and 2019 and played a key role in the company’s development and commercialization efforts of its technology portfolio including the scale-X single-use bioreactors range and the NevoLine™ biomanufacturing platform.

Today Mathias serves as General Manager at Univercells Technologies where he oversees the company’s operations and leads the company’s strategy development and implementation. It includes the commercialization of the company’s product portfolio as well as new technology developments to further expand the company’s market reach and success.

Mathias brings to the company over 10 years of experience and his dynamic savoir-faire in activities related to business strategy, operations, business planning and fundraising. 

Mathias holds a master in finance from Solvay Business School in Belgium.

Bob joined Univercells Technologies as Chief Operations Officer at the time of its creation in early 2020.  In this role, Bob brings focus to the completion of development of the technology portfolio as well as evolving the organization towards a reliable equipment supplier to the vaccine and gene therapy markets.

Bob brings 30+ years of experience in manufacturing, development and supply chain in plastics and clean assembly for packaging, invasive medical devices, and single-use systems for biopharma.  His experience includes more than a decade with GE and two operating companies of Danaher Corporation. 

Bob has extensive experience in the use of Lean and Six Sigma methodologies to bring efficiency in manufacturing and business processes.

Bob holds his Bachelors, Masters and PhD degrees in Chemical Engineering with focus on polymer processing. 

Matt is Co-Founder and President of Gamma Biosciences LLC, an investment platform formed in partnership with KKR & Co. focused on next-generation bioprocessing technologies and manufacturing for advanced therapies. 

Matt oversees the Gamma portfolio and is responsible for identifying and executing investments as well as driving growth, strategic and operational initiatives across Gamma’s operating companies. Matt was most recently Global Head of Business Development for GE Healthcare, where he was responsible for M&A and strategic alliances across the $19B healthcare division of GE.  Matt joined GE in 2011 and held a variety of other leadership positions in strategy, business development, venture investing and new business creation. 

Matt began his career as a corporate attorney at Sidley Austin LLP.  He holds a J.D. from the University of Michigan and a B.A. in Economics from Georgetown University.

Kugan Sathiyanandarajah (Menlo Park) joined KKR in 2010 and is a member of the Health Care industry team and Head of KKR’s Health Care Strategic Growth business in Europe.

He was previously a member of KKR’s European Private Equity platform, where he held joint responsibility for the Health Care industry team and has played a significant role in KKR’s investments in LGC Group, Walgreens Boots Alliance, Gamma Biosciences, Alvogen and Galenica. He currently serves on the board of directors of Gamma Biosciences and EchoNous.

Prior to joining KKR, he was with Goldman Sachs, where he was a member of the U.K. mergers and acquisitions team. Mr. Sathiyanandarajah earned an M.A. (First Class Hons) in Physical Natural Sciences (Chemistry) from the University of Cambridge.

Anuv Ratan joined KKR in 2017 and is a member of the Health Care industry team. At KKR, he has been involved with investments in Gamma Biosciences, Impel Neuropharma, Headlands Research, BrightSpring Pharmerica, Global Medical Response, Ajax Health, and Aimmune Therapeutics.

He is currently a member of the board of directors of Gamma Biosciences, Blue Sprig Pediatrics, and Headlands Research. Prior to joining KKR, Mr. Ratan was with FFL Partners, where he was involved in a number of health care transactions. Mr. Ratan began his career at The Blackstone Group. He holds an A.B., with honors, in Neurobiology from Harvard University.